Upstream Bio (UPB) Amortizatization of Intangibles (2023 - 2026)
Upstream Bio's quarterly Amortizatization of Intangibles came in at $754000.0 in Q1 2026, down 56.54% year-on-year from $1.7 million in Q1 2025, and up 154.96% quarter-over-quarter from -$1.4 million in Q4 2025.
Upstream Bio has reported Amortizatization of Intangibles for 4 years, with the latest figure at $754000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles fell 56.54% year-over-year to $754000.0; the trailing twelve-month figure through Mar 2026 stood at $521000.0 (down 81.17% YoY), and the FY2025 full-year result was $1.5 million, down 9.24% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $754000.0, up from -$1.4 million in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.7 million in Q1 2025, with the low at -$1.4 million in Q4 2025.
- Average Amortizatization of Intangibles over 4 years is $415900.0, with a median of $597500.0 recorded in 2024.
- Year-over-year, Amortizatization of Intangibles tumbled 375.0% in 2024 and jumped 178.49% in 2025.
- Tracing UPB's Amortizatization of Intangibles over 4 years: stood at $248000.0 in 2023, then plunged by 375.0% to -$682000.0 in 2024, then sank by 101.17% to -$1.4 million in 2025, then surged by 154.96% to $754000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $754000.0 (Q1 2026), -$1.4 million (Q4 2025), and $154000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | 754,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 754,000.00 |
| Mar 31, 2026 | 754,000.00 |
| Dec 31, 2025 | -1.37 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | 154,000.00 |
| Sep 30, 2025 | 154,000.00 |
| Jun 30, 2025 | 985,000.00 |
| Jun 30, 2025 | 985,000.00 |
| Mar 31, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.74 Mn |
| Dec 31, 2024 | -682,000.00 |
| Dec 31, 2024 | -682,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Sep 30, 2024 | 572,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 623,000.00 |
| Mar 31, 2024 | 623,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Dec 31, 2023 | 248,000.00 |